EGFR and neoplasm: Our data showed that icotinib-containing treatment reduced phosphorylation of EGFR, MAPK, and Akt proteins (Figure 2), suggesting that the changed activity of these proteins was not sufficient to inhibit tumor growth (comparing Table 2 data with Figure 2).